ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

2:00PM-3:30PM: Abstract Number: 2456

Lupus Patient Navigator Program to Improve Healthcare Barriers for Minority Patients

Abstracts: Healthcare Disparities in Rheumatology

2:00PM-3:30PM: Abstract Number: 2462

Mitochondrial-Mediated Neutrophil Activation in Dermatomyositis (DM) and Inclusion Body Myositis (IBM): Insights into Pathogenesis and Therapeutic Implications

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I

2:00PM-3:30PM: Abstract Number: 2466

Monoclonal Anti-MDA5 Autoantibodies Derived from a Patient with Dermatomyositis Target the Hel2i Domain of the MDA5 Protein

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I

2:00PM-3:30PM: Abstract Number: 2442

Neutrophils Induce Contact-Dependent Expansion of Arthritogenic Th17 Cells and Are Necessary for Disease in Experimental Ankylosing Spondylitis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science

2:00PM-3:30PM: Abstract Number: 2484

Optimizing the Care of the Rheumatic Patient with Rheumatologist-Pharmacist Co-management

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Predicting & Optimizing Outcomes

2:00PM-3:30PM: Abstract Number: 2487

Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity

Abstracts: SLE – Treatment II: Nonrenal

2:00PM-3:30PM: Abstract Number: 2481

Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Predicting & Optimizing Outcomes

2:00PM-3:30PM: Abstract Number: 2482

Preinflammatory Mesenchymal (PRIME) Cell Signature Genes Enrichment Predicts Treatment Response and Joint Prognosis in Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Predicting & Optimizing Outcomes

2:00PM-3:30PM: Abstract Number: 2439

Proteomic and Genomic Profiling of Plasma Exosomes from Ankylosing Spondylitis Patients

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science

2:00PM-3:30PM: Abstract Number: 2467

Quadriceps Muscle Fat Composition but Not Muscle Energetics Is Associated with Knee Osteoarthritis: Initial Results from the Study of Muscle, Mobility, and Aging

Abstracts: Osteoarthritis II: Novel Insights from Observational Studies

2:00PM-3:30PM: Abstract Number: 2493

Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis

Abstracts: Vasculitis – ANCA-Associated II

2:00PM-3:30PM: Abstract Number: 2459

Reporting of Race and Ethnicity in Lupus Publications in High-impact Rheumatology Journals

Abstracts: Healthcare Disparities in Rheumatology

2:00PM-3:30PM: Abstract Number: 2490

Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial

Abstracts: SLE – Treatment II: Nonrenal

2:00PM-3:30PM: Abstract Number: 2501

Selection of Indicators Reporting Response Rate in Pharmaceutical Trials for Systemic Lupus Erythematosus: Preference and Relative Sensitivity

Abstracts: Interprofessional OA & Lupus

2:00PM-3:30PM: Abstract Number: 2502

Self-Reported Sleep Disorders Among Individuals with Systemic Lupus Erythematosus

Abstracts: Interprofessional OA & Lupus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].